Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Tarsus Pharmaceuticals, Inc. (TARS : NSDQ)
 
 • Company Description   
Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.

Number of Employees: 46

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.70 Daily Weekly Monthly
20 Day Moving Average: 377,147 shares
Shares Outstanding: 20.73 (millions)
Market Capitalization: $283.96 (millions)
Beta: 1.44
52 Week High: $39.08
52 Week Low: $10.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.14% -16.94%
12 Week -22.77% -13.21%
Year To Date -39.11% -25.61%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
15440 LAGUNA CANYON ROAD SUITE 160
-
IRVINE,CA 92618
USA
ph: 949-409-9820
fax: -
ir@tarsusrx.com http://www.tarsusrx.com
 
 • General Corporate Information   
Officers
Bobak Azamian - President; Chief Executive Officer and Director
Michael Ackermann - Chairman
Leonard M. Greenstein - Chief Financial Officer
Bhaskar Chaudhuri - Director
Rosemary Crane - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 87650L103
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/03/22
Share - Related Items
Shares Outstanding: 20.73
Most Recent Split Date: (:1)
Beta: 1.44
Market Capitalization: $283.96 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.37 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.90
Price/Cash Flow: -
Price / Sales: 11.77
EPS Growth
vs. Year Ago Period: -308.51%
vs. Previous Quarter: -36.11%
Sales Growth
vs. Year Ago Period: -98.39%
vs. Previous Quarter: 59.47%
ROE
03/31/22 - -25.85
12/31/21 - -7.66
09/30/21 - -5.80
ROA
03/31/22 - -23.57
12/31/21 - -7.21
09/30/21 - -5.50
Current Ratio
03/31/22 - 14.18
12/31/21 - 15.33
09/30/21 - 18.05
Quick Ratio
03/31/22 - 14.18
12/31/21 - 15.33
09/30/21 - 18.05
Operating Margin
03/31/22 - -184.14
12/31/21 - -24.25
09/30/21 - -
Net Margin
03/31/22 - -184.14
12/31/21 - -24.25
09/30/21 - -
Pre-Tax Margin
03/31/22 - -185.21
12/31/21 - -24.15
09/30/21 - -18.42
Book Value
03/31/22 - 7.20
12/31/21 - 8.06
09/30/21 - 8.71
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.13
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 11.39
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©